Undertreatment of dyslipidemia: from the Arabian Gulf to the USA. Time to solve this problem!

Abstract

Undertreatment of dyslipideamia is a universal problem and reduces the efficasy of hypolipidaemic drugs to reduce cardiovascular event rates. The means to face this problem are available and should be utilized to optimize dyslipidaemia control and clinical outcomes.

Keywords::

• Arab Gulf
• Clinical benefit
• Measures to improve adherence
• Measures to improve lipid goal attainment
• Undertreatment of dyslipidemia

Transparency

Declaration of funding

This editorial was not funded. The authors did not receive financial or professional help with the preparation of the manuscript.

Declaration of financial/other relationships

The authors have given talks, attended conferences and participated in advisory boards and trials sponsored by various pharmaceutical companies. VGA is a member of the Editorial Board of CMRO and has nothing to declare, NK has lectured for AMGEN, NOVO, and MSD, and M.R. has lectured for Angelini, Abbott, and Lilly.